Frontiers in Molecular Biosciences (Apr 2022)
A Rapid, Highly Sensitive and Open-Access SARS-CoV-2 Detection Assay for Laboratory and Home Testing
- Max J. Kellner,
- Max J. Kellner,
- Max J. Kellner,
- Max J. Kellner,
- James J. Ross,
- James J. Ross,
- Jakob Schnabl,
- Jakob Schnabl,
- Marcus P. S. Dekens,
- Martin Matl,
- Martin Matl,
- Robert Heinen,
- Robert Heinen,
- Irina Grishkovskaya,
- Benedikt Bauer,
- Johannes Stadlmann,
- Johannes Stadlmann,
- Johannes Stadlmann,
- Luis Menéndez-Arias,
- Andrew D. Straw,
- Robert Fritsche-Polanz,
- Marianna Traugott,
- Tamara Seitz,
- Alexander Zoufaly,
- Manuela Födinger,
- Manuela Födinger,
- Christoph Wenisch,
- Johannes Zuber,
- Johannes Zuber,
- Vienna COVID-19 Detection Initiative (VCDI),
- Andrea Pauli,
- Julius Brennecke
Affiliations
- Max J. Kellner
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Max J. Kellner
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria
- Max J. Kellner
- Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria
- Max J. Kellner
- MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
- James J. Ross
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria
- James J. Ross
- Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria
- Jakob Schnabl
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria
- Jakob Schnabl
- Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria
- Marcus P. S. Dekens
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Martin Matl
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Martin Matl
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria
- Robert Heinen
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Robert Heinen
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria
- Irina Grishkovskaya
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Benedikt Bauer
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Johannes Stadlmann
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Johannes Stadlmann
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria
- Johannes Stadlmann
- Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria
- Luis Menéndez-Arias
- Centro de Biología Molecular “Severo Ochoa” (Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid), Madrid, Spain
- Andrew D. Straw
- Institute of Biology I and Bernstein Center Freiburg, Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany
- Robert Fritsche-Polanz
- Institute of Laboratory Diagnostics, Vienna, Austria
- Marianna Traugott
- 4th Medical Department with Infectious Diseases and Tropical Medicine, Vienna, Austria
- Tamara Seitz
- 4th Medical Department with Infectious Diseases and Tropical Medicine, Vienna, Austria
- Alexander Zoufaly
- 4th Medical Department with Infectious Diseases and Tropical Medicine, Vienna, Austria
- Manuela Födinger
- Institute of Laboratory Diagnostics, Vienna, Austria
- Manuela Födinger
- 0Sigmund Freud Private University, Vienna, Austria
- Christoph Wenisch
- 4th Medical Department with Infectious Diseases and Tropical Medicine, Vienna, Austria
- Johannes Zuber
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Johannes Zuber
- 1Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria
- Vienna COVID-19 Detection Initiative (VCDI)
- Andrea Pauli
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- Julius Brennecke
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria
- DOI
- https://doi.org/10.3389/fmolb.2022.801309
- Journal volume & issue
-
Vol. 9
Abstract
RT-qPCR-based diagnostic tests play important roles in combating virus-caused pandemics such as Covid-19. However, their dependence on sophisticated equipment and the associated costs often limits their widespread use. Loop-mediated isothermal amplification after reverse transcription (RT-LAMP) is an alternative nucleic acid detection method that overcomes these limitations. Here, we present a rapid, robust, and sensitive RT-LAMP-based SARS-CoV-2 detection assay. Our 40-min procedure bypasses the RNA isolation step, is insensitive to carryover contamination, and uses a colorimetric readout that enables robust SARS-CoV-2 detection from various sample types. Based on this assay, we have increased sensitivity and scalability by adding a nucleic acid enrichment step (Bead-LAMP), developed a version for home testing (HomeDip-LAMP), and identified open-source RT-LAMP enzymes that can be produced in any molecular biology laboratory. On a dedicated website, rtlamp.org (DOI: 10.5281/zenodo.6033689), we provide detailed protocols and videos. Our optimized, general-purpose RT-LAMP assay is an important step toward population-scale SARS-CoV-2 testing.
Keywords